Retatrutide and Liver Health: What the MASH/MASLD Research Shows
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated March 2026
Important: We are not doctors. Everything in this article is based on published research and publicly available clinical trial data. It is not medical advice. Talk to your physician before changing any medication or health protocol.
Key Takeaways
- Phase 2 data for retatrutide showed an 86% reduction in liver fat content at 24 weeks on the 12 mg dose (PMID 38858523). That is one of the most striking liver fat reduction numbers published for any compound in this class.
- MASLD (metabolic-associated steatotic liver disease) affects roughly 25% of adults globally. It is a major unmet medical need.
- Retatrutide's glucagon receptor component directly activates hepatic fat oxidation pathways. This is distinct from the liver benefits that come passively from weight loss alone.
- The TRIUMPH-5 trial is Eli Lilly's dedicated Phase 3 study of retatrutide in MASH (metabolic-associated steatohepatitis) patients.
- The first FDA-approved MASH drug (resmetirom) only targets the liver. Retatrutide addresses both obesity and liver disease simultaneously.
- Retatrutide is not FDA approved. All data discussed here is from clinical research, not approved treatment guidelines.
The Scale of the Problem
Liver disease rarely gets the same headlines as obesity or diabetes. That does not reflect its prevalence. For an overview of retatrutide across all indications, see our retatrutide guide.
MASLD (formerly called NAFLD) is the most common liver condition in the world. Conservative estimates put the global prevalence at 25% of adults. In the United States, that translates to roughly 80-100 million people living with some degree of metabolic liver disease.
The spectrum runs from simple fatty liver (steatosis) to metabolic-associated steatohepatitis (MASH, formerly NASH), which involves active inflammation and liver cell damage. Untreated MASH can progress to cirrhosis, liver failure, and hepatocellular carcinoma. It is a leading cause of liver transplants in the United States.
Until 2024, there were no approved drugs specifically for MASH. Resmetirom (Rezdiffra) changed that when it received FDA approval as the first targeted MASH treatment. But resmetirom only addresses liver pathways. It does not target the obesity that drives most cases of MASLD in the first place.
That gap is why retatrutide's liver data has drawn significant attention.
Why Retatrutide Might Be Different
To understand retatrutide's liver effects, you need to understand what the glucagon receptor does in the liver specifically.
The Glucagon Receptor Pathway
The liver is one of the primary organs where glucagon receptor activation produces meaningful effects. Glucagon signaling in hepatocytes (liver cells) triggers several key processes:
- Increased fatty acid oxidation: the liver breaks down stored fat rather than accumulating it
- Stimulation of lipophagy: cellular cleanup processes that clear lipid droplets from liver cells
- Reduction in lipogenesis: less new fat is synthesized from glucose
- Improved hepatic insulin sensitivity over time as fat content decreases
First-generation GLP-1 drugs like semaglutide do produce liver fat reduction, but this is primarily a secondary effect of overall weight loss and improved metabolic function. The glucagon component in retatrutide adds direct hepatic signaling on top of that.
This is a meaningful mechanistic distinction. It means retatrutide is not just reducing liver fat because the patient weighs less. It is also directly telling liver cells to oxidize fat through a separate signaling pathway.
GIP + GLP-1 + Glucagon: Three Pathways to One Liver
Retatrutide's triple receptor activation converges on the liver from multiple angles:
The GLP-1 component improves insulin sensitivity systemically, reducing the hyperinsulinemia that drives fat deposition in the liver. The GIP component further amplifies insulin secretion and may reduce hepatic gluconeogenesis. The glucagon component provides the direct fat oxidation signal discussed above.
No currently approved obesity drug targets all three of these pathways simultaneously.
The Phase 2 Liver Data
The core liver fat data for retatrutide comes from a substudy within the Phase 2 obesity trial, published in the peer-reviewed literature (PMID 38858523).
Key findings from this substudy:
- Participants on the 12 mg dose showed a mean 86% reduction in liver fat as measured by MRI-PDFF (magnetic resonance imaging proton density fat fraction) at 24 weeks
- This effect was dose-dependent, with lower doses showing proportionally smaller reductions
- The reduction occurred substantially faster than the weight loss curve, suggesting direct hepatic effects rather than just passive liver benefit from weight reduction
The 86% figure is notable in context. For comparison:
- Studies on semaglutide in patients with MASH have shown liver fat reductions, though the magnitude varies across trials (approximately 30-50% according to published MASH trials)
- Resmetirom (Rezdiffra), the first approved MASH drug, showed approximately 40-50% relative reduction in liver fat in the MAESTRO-NASH trial (published 2024)
- Retatrutide's 86% reduction in Phase 2 substantially exceeds both of these benchmarks, though again, Phase 2 data requires caution before direct comparison
The magnitude of this liver fat reduction is part of why TRIUMPH-5 was designed as a dedicated MASH trial rather than a secondary endpoint in a broader obesity study.
TRIUMPH-5: The Dedicated MASH Trial
Eli Lilly's TRIUMPH Phase 3 program includes multiple trials targeting different patient populations. TRIUMPH-5 is dedicated specifically to metabolic-associated steatohepatitis.
What TRIUMPH-5 is designed to answer:
- Does retatrutide produce meaningful improvement in MASH histology (liver biopsy-confirmed improvement in inflammation and fibrosis)?
- Can retatrutide achieve the FDA-defined endpoints for MASH approval: MASH resolution without worsening of fibrosis, or fibrosis improvement without worsening of MASH?
- What is the safety profile in a population selected for liver disease rather than pure obesity?
These are the same endpoints that resmetirom had to clear for its FDA approval. If retatrutide's Phase 3 MASH data is positive, it would potentially position it as the only drug that addresses both obesity and MASH through a single compound.
Results from TRIUMPH-5 are not yet available as of this writing.
The Obesity-MASH Connection
This context matters: MASLD is not a standalone disease. In the majority of cases, it is driven by metabolic dysfunction associated with obesity, insulin resistance, and elevated triglycerides.
Treating MASH without addressing the underlying obesity is treating a symptom rather than a cause. This is the core limitation of resmetirom: it is a liver-targeted therapy that does not affect body weight. Patients still need to address obesity separately.
Retatrutide's Phase 2 obesity data showed an average of 24.2% body weight loss at 48 weeks on the 12 mg dose (PMID 37366315). Combined with the direct liver fat reduction, this represents a potentially comprehensive metabolic intervention. Both the root cause (obesity, insulin resistance) and the end-organ manifestation (hepatic steatosis) are being targeted simultaneously.
From a clinical standpoint, this is a different treatment model than anything currently approved.
Fat Mass Reduction: Related but Distinct
Separate from liver fat, retatrutide's Phase 2 data also documented substantial changes in total fat mass composition. Fat mass reductions of -15.2%, -26.1%, and -23.2% were reported across dose groups (PMID 40609566).
The visceral adipose tissue (VAT) reduction is particularly relevant for liver health. Visceral fat (the fat surrounding abdominal organs) is metabolically active and directly contributes to hepatic fat accumulation through free fatty acid release into the portal circulation. Reductions in visceral adiposity have downstream liver benefits that extend beyond what body weight measurements capture.
What This Means for MASLD Patients Today
If you have been diagnosed with NAFLD, MASLD, or MASH, this research is relevant to understand, but it does not yet change what is available to you.
Retatrutide is not FDA approved. It is not available outside of clinical trials. TRIUMPH-5 is the trial to watch, but pivotal results are likely several years away.
What is available today:
- Resmetirom (Rezdiffra): The first FDA-approved MASH-specific drug. Liver-targeted. Does not affect weight.
- Lifestyle intervention: Still the first-line recommendation for MASLD. Studies consistently show that 7-10% body weight loss through diet and exercise produces significant liver fat reduction.
- Approved GLP-1 drugs (semaglutide, tirzepatide): Not approved for MASH, but some clinicians prescribe them off-label or for the obesity component while MASH is monitored. The data on liver fat reduction for these drugs is positive but not at retatrutide's Phase 2 magnitude.
The appropriate path is a conversation with a hepatologist or gastroenterologist familiar with the current MASH treatment landscape.
Frequently Asked Questions {#faq}
What is MASH and how is it different from NAFLD?
NAFLD (non-alcoholic fatty liver disease) has been renamed MASLD (metabolic-associated steatotic liver disease) in current guidelines. It refers to fat accumulation in the liver not caused by alcohol. MASH (metabolic-associated steatohepatitis, formerly NASH) is the more severe form where fat accumulation is accompanied by inflammation and liver cell damage. MASH carries a higher risk of progression to cirrhosis and liver failure.
How does retatrutide reduce liver fat?
Through at least two mechanisms. First, the glucagon receptor component directly activates hepatic fat oxidation pathways in liver cells, independent of weight loss. Second, overall weight loss and improved insulin sensitivity from GLP-1 and GIP receptor activation reduce the metabolic conditions that drive fat deposition in the liver.
How does the 86% liver fat reduction compare to other drugs?
The 86% reduction reported in Phase 2 (12 mg, 24 weeks) is substantially higher than published data for semaglutide or resmetirom in MASH populations. However, this is Phase 2 data versus Phase 3 data for approved drugs. Phase 2 results in smaller, selected populations do not always replicate in larger Phase 3 trials.
Is retatrutide better than resmetirom for MASH?
We do not know yet. Resmetirom is FDA approved and has Phase 3 histology data confirming MASH resolution. Retatrutide's TRIUMPH-5 Phase 3 trial has not yet published results. A direct comparison requires head-to-head trial data that does not currently exist.
Can I join a retatrutide clinical trial?
Eli Lilly's TRIUMPH Phase 3 trials are actively enrolling. You can search for open trials at clinicaltrials.gov using the search term "retatrutide." Enrollment criteria vary by specific trial. Talk to your physician about whether you might qualify.
Does weight loss alone fix fatty liver?
Research consistently shows that sustained weight loss of 7-10% of body weight produces meaningful liver fat reduction and can result in MASH remission in some patients. However, many patients cannot achieve or sustain this level of weight loss through lifestyle alone. This is part of why pharmacological interventions that target both obesity and liver disease simultaneously are under active development.
Related Reading
- Weight Loss and GI Disease: How Dropping Pounds Affects Your Gut and Liver
- Retatrutide vs. Tirzepatide: Triple Agonist vs. Dual Agonist
- Retatrutide vs. Survodutide: The Two Next-Gen Weight Loss Drugs Compared
- How GLP-1 Peptides Work: Mechanism, Dosing, and What the Research Shows
- Semaglutide vs. Liraglutide: How to Pick the Right GLP-1 for Your Situation
Medical Disclaimer
This article is produced by the Peptide Nerds editorial team for informational and educational purposes only. We are not physicians, pharmacists, or licensed healthcare providers. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendations.
Retatrutide is an investigational compound. It is not FDA approved for any indication. Resmetirom (Rezdiffra) is FDA approved for MASH but carries its own risks, contraindications, and prescribing requirements. All treatment decisions for liver disease should be made with a qualified hepatologist or gastroenterologist.
Always consult a qualified physician before starting, changing, or stopping any medication, supplement, or health protocol.
Sources
- Retatrutide liver fat reduction substudy, Phase 2. PMID 38858523
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315
- Rosenstock J, et al. Retatrutide Phase 1 Clinical Trial. Diabetes Care, 2023 — Early-phase retatrutide data
- Retatrutide fat mass and body composition data. PMID 40609566
- Preclinical glucagon receptor cancer signal research. PMID 40094000
- Meta-analysis, triple agonist outcomes. PMID 39817343
- Meta-analysis, retatrutide efficacy review. PMID 39318607
- Meta-analysis, next-gen obesity pharmacotherapy. PMID 38367045
Schema Markup
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "Organization",
"@id": "https://peptidenerds.com/#organization",
"name": "Peptide Nerds",
"url": "https://peptidenerds.com",
"logo": {
"@type": "ImageObject",
"url": "https://peptidenerds.com/images/logo.png"
}
},
{
"@type": "Article",
"@id": "https://peptidenerds.com/blog/retatrutide-liver-health-mash-nafld/#article",
"headline": "Retatrutide and Liver Health: What the MASH/MASLD Research Shows",
"description": "Retatrutide reduced liver fat by 86% at 24 weeks in Phase 2 trials. Here's what the research shows about its potential for MASH and MASLD treatment.",
"datePublished": "2026-03-13",
"dateModified": "2026-03-13",
"author": {
"@type": "Organization",
"name": "Peptide Nerds Editorial Team"
},
"publisher": {
"@id": "https://peptidenerds.com/#organization"
},
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://peptidenerds.com/blog/retatrutide-liver-health-mash-nafld/"
},
"image": {
"@type": "ImageObject",
"url": "https://peptidenerds.com/images/retatrutide-liver-health-mash-nafld.jpg"
},
"keywords": "retatrutide liver, retatrutide MASH, retatrutide NAFLD, MASLD treatment, TRIUMPH-5 trial, glucagon receptor liver"
},
{
"@type": "FAQPage",
"@id": "https://peptidenerds.com/blog/retatrutide-liver-health-mash-nafld/#faq",
"mainEntity": [
{
"@type": "Question",
"name": "What is MASH and how is it different from NAFLD?",
"acceptedAnswer": {
"@type": "Answer",
"text": "NAFLD has been renamed MASLD (metabolic-associated steatotic liver disease) in current guidelines. It refers to fat accumulation in the liver not caused by alcohol. MASH (metabolic-associated steatohepatitis) is the more severe form where fat accumulation is accompanied by inflammation and liver cell damage."
}
},
{
"@type": "Question",
"name": "How does retatrutide reduce liver fat?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Through at least two mechanisms. The glucagon receptor component directly activates hepatic fat oxidation pathways in liver cells, independent of weight loss. Additionally, overall weight loss and improved insulin sensitivity from GLP-1 and GIP receptor activation reduce the metabolic conditions that drive fat deposition in the liver."
}
},
{
"@type": "Question",
"name": "How does the 86% liver fat reduction compare to other drugs?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The 86% reduction reported in Phase 2 is substantially higher than published data for semaglutide or resmetirom in MASH populations. However, this is Phase 2 data versus Phase 3 data for approved drugs. Phase 2 results do not always replicate in larger Phase 3 trials."
}
},
{
"@type": "Question",
"name": "Is retatrutide better than resmetirom for MASH?",
"acceptedAnswer": {
"@type": "Answer",
"text": "We do not know yet. Resmetirom is FDA approved and has Phase 3 histology data confirming MASH resolution. Retatrutide's TRIUMPH-5 Phase 3 trial has not yet published results. A direct comparison requires head-to-head trial data that does not currently exist."
}
},
{
"@type": "Question",
"name": "Can I join a retatrutide clinical trial?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Eli Lilly's TRIUMPH Phase 3 trials are actively enrolling. You can search for open trials at clinicaltrials.gov using the search term 'retatrutide.' Enrollment criteria vary by specific trial. Talk to your physician about whether you might qualify."
}
},
{
"@type": "Question",
"name": "Does weight loss alone fix fatty liver?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Research consistently shows that sustained weight loss of 7-10% of body weight produces meaningful liver fat reduction and can result in MASH remission in some patients. However, many patients cannot achieve or sustain this level of weight loss through lifestyle alone."
}
}
]
}
]
}
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.